abdullah's picture
Add files using upload-large-folder tool
cee63d3 verified
raw
history blame
17.7 kB
1
00:00:03,100 --> 00:00:06,680
ุจุณู… ุงู„ู„ู‡ ุงู„ุฑุญู…ู† ุงู„ุฑุญูŠู… ุงุณุชูƒู…ุงู„ุง ู„ู…ุญุงุถุฑุฉ non non
2
00:00:06,680 --> 00:00:09,860
-lochemical malignant ุงูˆ lymph proliferative
3
00:00:09,860 --> 00:00:16,240
disorders ู‡ู†ุงุฎุฏ ู…ุซุงู„ ุงุฎุฑ ูˆู‡ูˆ ุงู„ Hodgkin disease ุงู„
4
00:00:16,240 --> 00:00:18,600
Hodgkin disease ู‡ูˆ ุนุจุงุฑุฉ ุนู† neo plastic disorder
5
00:00:18,600 --> 00:00:23,920
ุจูŠูƒูˆู† ููŠู‡ ุฎู„ูŠุฉ ุจูŠุชู…ูŠุฒ ุจูˆู„ูˆุฏ ุฎู„ูŠุฉ ุจูŠุณู…ูˆู‡ุง Red
6
00:00:23,920 --> 00:00:30,220
Steinberg cell ูˆ ุงู„ Red Steinberg cell ู‡ุฐู‡ ุบุฑูŠุจุง
7
00:00:30,220 --> 00:00:35,290
ุจุชู†ุดุฃ ู…ู† ุงู„ lymph nodesูˆ it's restricted only to
8
00:00:35,290 --> 00:00:41,430
the lymph nodes it's not ูŠุนู†ูŠ it can spread to the
9
00:00:41,430 --> 00:00:46,310
contiguous group of lymph node ุฅู†ู…ุง ุชุทู„ุน ุจุฑุง ุงู„
10
00:00:46,310 --> 00:00:50,790
lymph node ูŠุนู†ูŠ it's very rare ูˆ ุบุงู„ุจุง ุจู…ุง ุฃู†ู†ุง
11
00:00:50,790 --> 00:00:53,410
ุจู†ุญูƒูŠ ุนู„ู‰ lymph node involvement ูŠุจู‚ู‰ ุจู†ุญูƒูŠ ุนู„ู‰
12
00:00:53,410 --> 00:00:57,890
ุงู„ู„ูŠ ู‡ูˆ defective immunity ู„ุฅู† ุณุงุญุงุช ุงู„ู…ุนุงุฑูƒ ููŠ
13
00:00:57,890 --> 00:01:00,190
ุงู„ุฌุณู… ู‡ูŠ ุนุจุงุฑุฉ ุนู† ุงู„ lymph nodes
14
00:01:07,510 --> 00:01:12,550
ุงู„ุงู†ุณุฏู†ุณ ุงู„ุงู†ุณุฏู†ุณ ู…ู† ุญู„ุชูŠู† ู„ุงุฑุจุน ุญุงู„ุงุช ู„ูƒู„ ู…ุฆุฉ ุงู„ู
15
00:01:12,550 --> 00:01:16,830
ู…ู† ุงู„ population ููŠ ุงู„ุณู†ุฉ ูˆุงู„ูˆ by model age
16
00:01:16,830 --> 00:01:19,870
distribution ุจูŠุตูŠุจ ุงู„ู†ุงุณ ููŠ ุงู„ุณู† ุฎู…ุณุชุงุดุฑ ู„ุฎู…ุณุฉ ูˆ
17
00:01:19,870 --> 00:01:24,190
ุชู„ุงุชูŠู† ุณู†ุฉ ูˆ ุจูŠุตูŠุจ ุงู„ู†ุงุณ ุงู„ู„ูŠ ููˆู‚ ุงู„ุฎู…ุณูŠู† ุณู†ุฉ ุงู„
18
00:01:24,190 --> 00:01:27,230
male ูƒุงู„ุนุงุฏุฉ ุงูƒุชุฑ ู…ู† ุงู„ female one point seven to
19
00:01:27,230 --> 00:01:35,630
one ูˆุงู„ pathophysiology ุงู†ู‡ ุงู‡ู… ุญุงุฌุฉุฅู† ุงู„ู…ุฑูŠุถ
20
00:01:35,630 --> 00:01:40,230
ุบุงู„ุจุง ูŠุนุงู†ูŠ ู…ู† painless at presentation ูŠุนู†ูŠ
21
00:01:40,230 --> 00:01:44,610
ูˆูŠุนุงู†ูŠ ู…ู† painlessness ูŠุนู†ูŠ asymmetrical
22
00:01:44,610 --> 00:01:50,610
enlargement of lymph nodes ูŠุนู†ูŠ ู…ุงููŠุด ุฃู„ู… ููŠ ุงู„
23
00:01:50,610 --> 00:01:54,850
lymph nodes enlargement which lymph node ู‚ุงู„ูˆุง ุฅู…ุง
24
00:01:54,850 --> 00:01:59,450
cervical or subclavicular lymph nodes ู„ูƒู† ู‡ุฐุง ู„ุง
25
00:01:59,450 --> 00:02:04,270
ูŠุณุชุซู†ู‰ ุงู„ auxiliary ูˆ ุงู„inguinal or femoralู…ุงุดูŠ
26
00:02:04,270 --> 00:02:07,130
ุจูŠุฌูŠ ุงู„ู…ุฑูŠุถ ุจูŠูƒูˆู† ุนู†ุฏู‡ lymph node enlargement
27
00:02:07,130 --> 00:02:16,170
ุจุชุญุณุณู‡ุง ููŠู‡ ุฃู„ู…ุŸ ู„ุฃ ูุงุด ุฃู„ู… ูˆุจุงู„ุชุงู„ูŠ ุจูŠูƒูˆู† this
28
00:02:16,170 --> 00:02:22,350
is at presentation ูŠุนู†ูŠ ุนู†ุฏ ุงู„ุชุดุฎูŠุต ุงู„ู„ูŠ ุงู„ lymph
29
00:02:22,350 --> 00:02:24,930
nodes ู…ู…ูƒู† ูŠูƒูˆู† ู…ุตุญูˆุจ generalized etching
30
00:02:28,030 --> 00:02:30,710
ุจุงู„ู…ู‚ุงุฑู†ุฉ ู…ุน ุงู„ู€ Non-Hodgkin lymphoma ุนุงุฏุฉ ุงู„ู€
31
00:02:30,710 --> 00:02:33,110
Hodgkin disease ุจูŠูƒูˆู† Restricted at presentation
32
00:02:33,110 --> 00:02:38,650
ููŠ ุญูŠู† ุงู„ู€ Non-Hodgkin lymphoma ุชูƒูˆู† Systemic ุงูˆ
33
00:02:38,650 --> 00:02:44,950
Disseminated at presentation ุงู„ presence of Alexia
34
00:02:44,950 --> 00:02:47,590
ูˆ Night sweating ูŠุนู†ูŠ ุบุงู„ุจุง associated with
35
00:02:47,590 --> 00:02:53,130
advanced disease Clinical presentation ูŠุนู†ูŠ ุจูŠูƒูˆู†
36
00:02:53,130 --> 00:02:56,470
Non tender lymph node enlargementุณูˆุงุก ูƒุงู† ููŠ
37
00:02:56,470 --> 00:03:02,570
ุงู„ู†ุงู‚ุต ุฃูˆ ู…ูŠุฏูŠุงุณุชูŠู†ุง ุฃูˆ ุงู„ุงุฏูŠู†ูˆุจุงุชูŠ ุงู‚ุฏูˆู…ู† ุงูƒุชุฑุงู†ูˆ
38
00:03:02,570 --> 00:03:06,890
ุฏู„ ุฏูŠุฒูŠุฒ ุณูŠุณุชูŠู†ูŠูƒุณ ุณูŠู…ุชูˆู… ุฒูŠ ุงู„ููŠุจุฑ ู†ุงูŠุช ูˆุดูˆูŠุชู†ุฌ
39
00:03:06,890 --> 00:03:12,290
ุงู†ูƒุณุจู„ูŠู† ูˆูˆูŠุช ู„ูˆุณ ูƒู…ุงู† ูˆ ุงุฎุฑ ุณูŠู…ุชูˆู… ุฒูŠ ุงู„ูุชูŠู‚
40
00:03:12,290 --> 00:03:16,230
ูˆูˆูŠูƒู†ุณ ุจูˆุฑุงูŠุชุณ ุจูˆุฑุงูŠุชุณ ุงู„ุญูƒุฉ ูƒุงู ูˆchest pain
41
00:03:16,230 --> 00:03:21,750
shortness of breath ูˆููŠู†ุง ูƒุงูุง ุณู†ุฏุฑูˆู… ูˆ ุงู„ุงุจุฏูˆู…ู†ุงู„
42
00:03:21,750 --> 00:03:27,790
painPower disturbances, ascites ูˆ ุจูˆู…ุจูŠู† ูƒู„ ู‡ุฐุง
43
00:03:27,790 --> 00:03:35,230
ุนุจุงุฑุฉ ุนู† symptoms ู„ู…ุฑุถู‰ recognition ุบูŠุฑูˆุง
44
00:03:35,230 --> 00:03:40,370
ู‡ุฐุง ุงู„ู…ุฑุถ ุงู„ุฏู… ุจูŠูƒูˆู† ุฎุงู„ูŠ ุชู…ุงู…ุง ุงู„ peripheral
45
00:03:40,370 --> 00:03:43,410
blood ู…ุง ุจู†ุดูˆู ููŠู‡ ุงูŠ ุญุงุฌุฉ ุฃูˆ ุญุชู‰ ุงู„ bone marrow
46
00:03:43,410 --> 00:03:47,790
is not involved ุนุดุงู† ู‡ูŠ ูƒู‡ุฏุฃ disease of
47
00:03:47,790 --> 00:03:53,090
pathologist ู…ุด disease of hematologist ู„ูƒู†ุจู…ุง ุฃู†
48
00:03:53,090 --> 00:04:00,290
ุงู„ู€ bone marrow ูŠุนู†ูŠ is ุงู„ .. ุงู„ hematologically
49
00:04:00,290 --> 00:04:05,570
affected ูŠุนู†ูŠ ุชุชุฑู‚ู†ุง ุฅู„ู‰ ู‡ุฐุง ุงู„ู…ุฑุถ ุจูˆูƒูŠุฒูŠุง ู…ุง ุงู„
50
00:04:05,570 --> 00:04:08,290
man's passive changes such as myelotrombocytosis
51
00:04:08,290 --> 00:04:14,810
ู†ุชุฑูˆููŠู„ูŠุง relative eczemophilia is present ูˆ ุฌู…ูŠุน
52
00:04:14,810 --> 00:04:18,430
ุงู„ุฃู…ูŠู…ูŠุง ูˆุงู„ุงู†ูุณุงูŠุชูˆุจูŠู…ูŠุง ูˆุงู„ู„ูŠูƒูˆุงุฑุชุฑูˆุจู„ุงุณุชูˆุณุชุณ
53
00:04:18,430 --> 00:04:23,180
ูƒู„ู‡ู… ุจูŠูŠุนู†ูŠ ูˆุฌูˆุฏู‡ู… ุจูŠุนู†ู‰ ุงู† ุงู„ู…ุฑุถ in its advanced
54
00:04:23,180 --> 00:04:31,620
stage ู„ูƒู† ุงู„ู„ูŠ ุจูŠู…ุฑ is not involvement is only
55
00:04:31,620 --> 00:04:37,900
involved in advanced stage ู„ูƒู†ู‡ it's uncommon at
56
00:04:37,900 --> 00:04:43,960
presentationุงู„ุฃู‡ู… ุญุงุฌุฉ ุงู† ู†ุงุฎุฏ ุนูŠู†ุฉ ู…ู† ุงู„ lymph
57
00:04:43,960 --> 00:04:50,180
node ุจูŠูˆุจุณูŠ ูˆ ู†ุดูˆู ูˆ ู†ุฏูˆุฑ ุนู„ูŠู‡ุง ุงู„ู„ูŠ ู‡ูˆ presence
58
00:04:50,180 --> 00:04:55,260
of infiltrate ู„ุฎู„ุงูŠุง ูƒุซูŠุฑุฉ ูŠุชุฎู„ู„ ู‡ุฐู‡ ุงู„ุฎู„ุงูŠุง ุงู„ู„ูŠ
59
00:04:55,260 --> 00:05:01,120
ู‡ูˆ ุงู„ RS cell ูˆ ุถุฑูˆุฑูŠ ุฌุฏุง ูˆุฌูˆุฏ ุงู„ RS cell ู„ู„ุชุดุฎูŠุต
60
00:05:02,360 --> 00:05:06,520
ูˆุฅู† ูƒุงู† ู„ูŠุณ ู…ุญุฏูˆุฏ ู„ุฃู†ู‡ ุจู†ุดูˆูู‡ุง ููŠ ุฃู…ุฑุงุถ ุฃุฎุฑู‰ ุฒูŠ
61
00:05:06,520 --> 00:05:08,240
ุงู„ู€ Non-Hodgkin lymphoma ุฃูˆ ุงู„ู€ Chronic
62
00:05:08,240 --> 00:05:12,160
lymphocytic leukemia ุบูŠุฑ ุงู„ู€ Hodgkin disease ุงู„ู€
63
00:05:12,160 --> 00:05:16,120
RS cell is typically ู‡ูŠ ุนุจุงุฑุฉ ุนู† large cell ููŠู‡ุง
64
00:05:16,120 --> 00:05:22,440
two or more large oval nuclei ูƒู„
65
00:05:22,440 --> 00:05:27,480
ูˆุงุญุฏุฉ ู…ู†ู‡ู… ููŠู‡ุง ู†ูŠูƒู„ูŠูˆู„ุงุณ ูˆ ุงู„ู†ูŠูƒู„ูŠูˆู„ุงุณ is
66
00:05:27,480 --> 00:05:32,700
separated from ุงู„ nuclear membraneby a clear zone
67
00:05:32,700 --> 00:05:37,020
ูŠุนู†ูŠ ููŠ ูุฑู‚ ู…ุง ุจูŠู† ุงู„ู€ nucleoli ูˆ ุงู„ nuclear
68
00:05:37,020 --> 00:05:40,900
membrane classification
69
00:05:40,900 --> 00:05:44,380
ุนู…ู„ูˆุง classification according to the pattern of
70
00:05:44,380 --> 00:05:52,700
infiltration ู„ู„ lymph node biopsy ูู‚ุณู…ูˆู‡ุง ุฅู„ู‰ ุฃุฑุจุน
71
00:05:52,700 --> 00:05:56,180
ุญุงู„ุงุช ู…ุฑุถูŠุฉ ูˆ ุงู„ูˆุงุญุฏ ุงู„ lymphocyte predominant ูˆ
72
00:05:56,180 --> 00:06:01,160
ู…ู† ุงู„ุฅุณู… ุจูŠูƒูˆู† ููŠ infiltrate ู…ู„ูŠุงู† ุจุงู„ lymphocytes
73
00:06:03,080 --> 00:06:07,420
ุงู„ู†ูˆุน ุงู„ุชุงู†ูŠ Nodular Sclerosis ุจูŠูƒูˆู† ููŠู‡ ุงู„ู„ูŠ ู‡ูˆ
74
00:06:07,420 --> 00:06:13,660
ุชุฌู…ุน ุญู„ู‚ูŠ ู„ู„ Infiltrate
75
00:06:13,660 --> 00:06:18,240
ูˆ ุจุฑุถู‡ ุจูŠุชุฎู„ู„ู‡ ุงู„ RS Cell ู„ูƒู† ุงู„ RS Cell ุจุชุชู…ูŠุฒ
76
00:06:18,240 --> 00:06:23,680
ุจุดูƒู„ ู…ุฎุชู„ู ูˆ ู‡ูˆ ุงู„ lacunar cell ุจูŠุณู…ูˆู‡ุง lacunar
77
00:06:23,680 --> 00:06:27,340
cell ุงู„ู„ูŠ ุจูŠูƒูˆู† ููŠู‡ุง ุงู„ cytoplasm is contracted
78
00:06:27,340 --> 00:06:35,930
ู…ุถุบูˆุท ุดูˆูŠุฉ ูˆ ูƒุฃู†ู‡ูƒุฃู†ู‡ุง ุนุจุงุฑุฉ ุนู† Artifact Sclerosis
79
00:06:35,930 --> 00:06:41,210
ุฃูŠุถู‹ุง ู…ูˆุฌูˆุฏ ู†ุชูŠุฌุฉ ูƒู„ุงุฌุฉ ุจุฑุถู‡ ู‚ุณู…ูˆู‡ ุฅู„ู‰ ุฃุฎุตุงู…
80
00:06:41,210 --> 00:06:45,890
ู…ุฎุชู„ูุฉ ู‡ุฐุง ุจูŠุตูŠุจ ุงุฑุจุนูŠู† ููŠ ุงู„ู…ูŠุฉ ุงูˆ ุจูŠุดูƒู„ ุงุฑุจุนูŠู†
81
00:06:45,890 --> 00:06:50,870
ููŠ ุงู„ู…ูŠุฉ ู…ู† ุงู„ุญุงู„ุงุช ูˆุบุงู„ุจู‹ุง associated with thymic
82
00:06:50,870 --> 00:06:56,110
origin ูˆูŠูˆุฌุฏ Prognosis ุงู„ู†ูˆุน ุงู„ุชุงู„ุช ุงู„ู„ูŠ ู‡ูˆ Mixed
83
00:06:56,110 --> 00:06:58,390
Cellularity ู…ู† ุงู„ุงุณู… ูŠุนู†ูŠ ููŠู‡ ุงูƒุชุฑ ู…ู† ู†ูˆุน ู…ู†
84
00:06:58,390 --> 00:06:58,970
ุงู„ุฎู„ุงูŠุง
85
00:07:02,620 --> 00:07:07,380
ุงู„ู€ RS Cell ุจุชูƒูˆู† ุฃูŠุถู‹ุง Scattered Within These
86
00:07:07,380 --> 00:07:11,500
Cells Lymphocyte Depleted ู…ู† ุงู„ุฅุณู… ู…ุงููŠุด
87
00:07:11,500 --> 00:07:18,000
Lymphocytes ุจุชูƒูˆู† ุฎู„ุงูŠุง ูƒุจูŠุฑุฉ ุงู„ู€ RS ูˆู…ุตุญูˆุจุฉ
88
00:07:18,000 --> 00:07:21,940
ุจHesticide ู„ูƒู† ุงู„ู€ Lymphocyte is scantูŠ scant ูŠุนู†ูŠ
89
00:07:21,940 --> 00:07:28,540
ู‚ู„ูŠู„ ุงู„ Immunophenotyping ูŠุนู†ูŠ ุจูŠุชูƒู„ู… ู…ู† ุฎู„ุงูŠุง
90
00:07:30,220 --> 00:07:36,900
ุงู„ู€ RS ุฃูˆ ุงู„ู€ Red Stamp Excel ุนู„ู‰ ุณุทุญ CD25ุŒ IL-2
91
00:07:36,900 --> 00:07:44,220
ุฑูŠุณุจุชูˆุฑุŒ CD15 ูˆ CD30 ูˆูŠู‚ุณู…ูˆุง ุงู„ุฃู†ูˆุงุน ุฅู„ู‰ B ูˆT
92
00:07:44,220 --> 00:07:48,240
ู„ูŠู†ููˆุณุงูŠุช ูุฌุงู„ูˆุง ุงู„ู€ NS ุงู„ู„ูŠ ู‡ูˆ nodular sclerosis
93
00:07:48,240 --> 00:07:51,320
ูˆ ุงู„ู€ mixed similarity ู‡ู… ุนุจุงุฑุฉ ุนู† B ู„ูŠู†ููˆูŠุฏ
94
00:07:51,320 --> 00:07:57,620
ู…ุงู„ูŠุฌู†ุงู†ุณูŠ ุจูŠู†ู…ุง ุงู„ู„ูŠู†ููˆุณุงูŠุช predominant ู‡ูŠ ุนุจุงุฑุฉ
95
00:07:57,620 --> 00:08:02,790
ุนู† T ู„ูŠู†ููˆูŠุฏ ู…ุงุฑูƒุฑุนู…ู„ูˆุง staging ู„ู„ู…ุฑุถ ุฌุงู„ูˆ ููŠู‡
96
00:08:02,790 --> 00:08:05,910
ุฃุฑุจุน stages ู†ู…ุฑุฉ ูˆุงุญุฏ ุงู„ู„ูŠ ู‡ูŠ involvement of
97
00:08:05,910 --> 00:08:09,390
single lymph nodes ู†ู…ุฑุฉ ุงุชู†ูŠู† ููŠู‡ ุชู†ุชูŠู† ุงูˆ ุงูƒุชุฑ ู…ู†
98
00:08:09,390 --> 00:08:11,530
lymph nodes are involved ู„ูƒู† at the same
99
00:08:11,530 --> 00:08:14,590
anatomical
100
00:08:14,590 --> 00:08:18,770
sides ู†ู…ุฑุฉ ุชู„ุงุชุฉ ููŠ involvement of lymph node
101
00:08:18,770 --> 00:08:23,200
region on both sides of the bodyูˆุงู„ู†ู…ุฑุฉ ุฃุฑุจุนุฉ
102
00:08:23,200 --> 00:08:25,940
ุจูŠุตูŠุฑ ููŠู‡ diffuse or disseminated involvement
103
00:08:25,940 --> 00:08:33,480
ู„ูˆุงุญุฏ ุฃูˆ ุฃูƒุชุฑ ู…ู† ูˆุงุญุฏ ู„ู‡ extra lymphatic organ ุจ
104
00:08:33,480 --> 00:08:36,520
.. with or without associated lymph node
105
00:08:36,520 --> 00:08:43,080
involvement treatment ุญุณุจ ุงู„ stage ุงู„ early stage
106
00:08:43,080 --> 00:08:47,420
ุจุฏู‡ุง localized radiotherapy ุจูŠู†ู…ุง ุงู„ advanced
107
00:08:47,420 --> 00:08:52,940
stage ุจุฏู‡ุง chemotherapy ุงู„ prognosisุทุจุนุงู‹ ูˆุฌุฏูˆุง
108
00:08:52,940 --> 00:08:58,520
ุฃู†ู‡ 80% ู…ู† ุญุงู„ุงุช ุงู„ู„ูŠ ุจุชุฌูŠู†ุง ููŠ stage number one ูˆ
109
00:08:58,520 --> 00:09:01,580
ุฃูƒุชุฑ ู…ู† 50% ู…ู† stage number four of Hodgkin
110
00:09:01,580 --> 00:09:05,400
disease ู…ู…ูƒู† ูŠุนูŠุด ุนุดุฑ ุณู†ูˆุงุช ุฃูˆ ุฃูƒุชุฑ at the
111
00:09:05,400 --> 00:09:10,760
presentation ุทุจุนุงู‹ ู‡ุฐุง ุจูŠุนุชุจุฑ ู†ูˆุน ู…ู† ุฃู†ูˆุงุน ุงู„ุดูุงุก
112
00:09:10,760 --> 00:09:15,300
ูˆุจู‡ูŠูƒ ุจู†ูƒูˆู† ุบุทูŠู†ุง ุงู„ Hodgkin disease ู„ู…ุง ุฃู†
113
00:09:15,300 --> 00:09:23,580
Hodgkin lymphoma ู‡ุฐุง ุนุงู„ู… ุขุฎุฑูˆ ุนุงุฏุฉ ุจูŠ .. ูŠุนู†ูŠ ููŠ
114
00:09:23,580 --> 00:09:30,740
ู…ู†ู‡ ูƒุชุจ ููŠ ู‡ุฐุง ุงู„ hemopoietic malignancy ูˆ ู‡ุฐู‡
115
00:09:30,740 --> 00:09:35,900
ุชู‚ุณูŠู…ุฉ ู„ูƒู„ ุงู„ malignant hematological
116
00:09:35,900 --> 00:09:40,100
malignancy ู‡ูŠ ุงู„ myeloproliferative ูˆ ุฅูŠุด ุจุชุดูƒู„
117
00:09:40,100 --> 00:09:43,900
ุจูƒูŠู…ูŠุง ูˆ ุฅูŠุด ููŠ ุฃู†ูˆุงุน ูˆ ุงู„ malignant lymphomaูˆุฃุญู†ุง
118
00:09:43,900 --> 00:09:47,320
ู‚ู„ู†ุง ุงู„ู€ Hodgkin ูˆ ุงู„ู€ Non-Hodgkin ุงู„ู„ูŠ ุจุชู†ู‚ุณู… ุฅู„ู‰
119
00:09:47,320 --> 00:09:50,060
Perkins Lymphoma ูˆ Cutaneous T Cell Leukemia
120
00:09:50,060 --> 00:09:56,560
ู„ู„ู…ููˆู…ุฉ ูˆ ู‡ูƒุฐุง Non-Hodgkin Lymphoma by definition
121
00:09:56,560 --> 00:09:59,920
ู‡ูŠ ุจู„ุนู†ุฉ heterogeneous group of B Anti-Cell
122
00:09:59,920 --> 00:10:03,700
Malignancy ุงู„ู„ูŠ ู‡ูŠ that are diverse in cellular
123
00:10:03,700 --> 00:10:08,060
origin and morphologyุงู†ุตุงุฆูŠุงุช ุงู„ุฌูŠู†ุงุชูŠูƒ ูˆุงู†ุตุงุฆูŠุงุช
124
00:10:08,060 --> 00:10:08,560
ุงู„ุงู†ุตุงุฆูŠุงุช ุงู„ุงู†ุตุงุฆูŠุงุช ุงู„ุงู†ุตุงุฆูŠุงุช ุงู„ุงู†ุตุงุฆูŠุงุช
125
00:10:08,560 --> 00:10:10,620
ุงู„ุงู†ุตุงุฆูŠุงุช ุงู„ุงู†ุตุงุฆูŠุงุช ุงู„ุงู†ุตุงุฆูŠุงุช ุงู„ุงู†ุตุงุฆูŠุงุช
126
00:10:10,620 --> 00:10:11,920
ุงู„ุงู†ุตุงุฆูŠุงุช ุงู„ุงู†ุตุงุฆูŠุงุช ุงู„ุงู†ุตุงุฆูŠุงุช ุงู„ุงู†ุตุงุฆูŠุงุช
127
00:10:11,920 --> 00:10:19,200
ุงู„ุงู†ุตุงุฆูŠุฉ ุงู„ุงู†ุตุงุฆูŠุฉ ุงู„ุงู†ุตุงุฆูŠุฉ ุงู„ุงู†ุตุงุฆูŠุฉ ุงู„ุงู†ุตุงุฆูŠุฉ
128
00:10:19,200 --> 00:10:21,860
ุงู„ุงู†ุตุงุฆูŠุฉ ุงู„ุงู†ุตุงุฆูŠุฉ ุงู„ุงู†ุตุงุฆูŠุฉ ุงู„ุงู†ุตุงุฆูŠุฉ ุงู„ุงู†ุตุงุฆูŠุฉ
129
00:10:21,860 --> 00:10:23,400
ุงู„ุงู†ุตุงุฆูŠุฉ ุงู„ุงู†ุตุงุฆูŠุฉ ุงู„ุงู†ุตุงุฆูŠุฉ ุงู„ุงู†ุตุงุฆูŠุฉ ุงู„ุงู†ุตุงุฆูŠุฉ
130
00:10:23,400 --> 00:10:24,260
ุงู„ุงู†ุตุงุฆูŠุฉ ุงู„ุงู†ุตุงุฆูŠุฉ ุงู„ุงู†ุตุงุฆูŠุฉ ุงู„ุงู†ุตุงุฆูŠุฉ ุงู„ุงู†ุตุงุฆูŠุฉ
131
00:10:24,260 --> 00:10:27,800
ุงู„ุงู†ุตุงุฆูŠุฉ ุงู„ุงู†ุตุงุฆูŠุฉ ุงู„ุงู†ุตุงุฆูŠุฉ ุงู„ุงู†ุตุงุฆูŠุฉ ุงู„ุงู†ุตุงุฆูŠุฉ
132
00:10:27,800 --> 00:10:32,660
ุงู„ุงู†ุตุงุฆูŠุฉ ุงู„ุงู†ุตุงุฆูŠุฉ
133
00:10:37,010 --> 00:10:42,950
ุงู„ุชุญุฏูŠุงุช ุงู„ุฃุฎูŠุฑุฉ ุงู‚ุชู†ุนุช ุจุฅุนุงุฏุฉ ุฅุจุดุชุบุงู„ ุงู„ุจุฑุจุงุฑูŠุณ
134
00:10:42,950 --> 00:10:46,890
ุงู„ู…ุฑุชุจุท ุจุงู„ุฅู†ู‚ุงุฐ ู…ู† ุงู„ู€ Non-Hodgkin lymphoma
135
00:10:46,890 --> 00:10:54,410
.ุงู„ุชุนู„ูŠู‚ ุงู„ุฅุจุฏูŠู…ูŠูˆู„ูˆุฌูŠ ุฃูŠุถู‹ุง ุฃุธู‡ุฑ ุชุฌุงุฑุจ ุตุบูŠุฑุฉ ู…ู†
136
00:10:54,410 --> 00:10:58,600
ุงู„ู€ Non-Hodgkin lymphomaุจูŠู† ุงู„ู†ุงุณ ุงู„ู…ุฒุงุฑุนูŠู† ูˆ ุงู„
137
00:10:58,600 --> 00:11:07,320
rubber industry people ูˆ their significance of
138
00:11:07,320 --> 00:11:13,880
their of this observation still in doubt ุณุงุนุชู‡
139
00:11:13,880 --> 00:11:15,800
genetic abnormality ูˆุฌุฏูˆุง ููŠู‡ ูƒุฑู…ุฒูˆู… ุงู„
140
00:11:15,800 --> 00:11:18,860
abnormality ููŠู‡ ุฃูƒุชุฑ ู…ู† ูƒุฑู…ุฒูˆู… ุฒูŠ ุงุชู†ูŠู† ูˆ ุชู„ุงุชุฉ ูˆ
141
00:11:18,860 --> 00:11:22,100
ุณุจุนุฉ ูˆ ุงุชู†ุงุดุฑ ูˆ ุงุฑุจุชุงุด ูˆ ุชู…ุงู†ุชุงุด ูˆ ุงู„
142
00:11:22,100 --> 00:11:24,840
pathophysiology ู‚ุงู„ูˆุง ูŠุญุตู„ ููŠู‡ lymphomas with
143
00:11:24,840 --> 00:11:29,480
follicular patternovergrowth ุจุชูƒูˆู† less aggressive
144
00:11:29,480 --> 00:11:34,060
than diffuse pattern ู†ู…ุฑุฃุชูŠู† small lymphocytic
145
00:11:34,060 --> 00:11:39,060
lymphoma ุฃู‚ู„ ุดุฑุงุณุฉ ู…ู† ุงู„ large cell lymphoma
146
00:11:39,060 --> 00:11:45,800
ู†ู…ุฑุฃุชู„ุงุชุฉ ุจุงู„ู…ู‚ุงุฑู†ุฉ ุจุงู„ุฃูƒูŠุฏ ู„ูˆูƒูŠู…ูŠุง ุจุนุฏ ุงู„ high
147
00:11:45,800 --> 00:11:48,980
grade lymphoma are more amenable to treatment
148
00:11:48,980 --> 00:11:55,180
ู‚ุงุจู„ุฉ ู„ู„ุนู„ุงุฌ ุนู„ู‰ ุนูƒุณ ุงู„ chronic types of leukemia
149
00:11:57,020 --> 00:12:00,120
ุฃูŠุถุง in contrast to Hodgkin disease ุงู„ู€ non
150
00:12:00,120 --> 00:12:03,460
Hodgkin lymphoma is disseminated at presentation
151
00:12:03,460 --> 00:12:10,700
ู‡ู†ุงูƒ ุจุชูƒูˆู† localized ู‡ุฐู‡ ุชู‚ุณูŠู…ุฉ 85% ู…ู† ุงู„ู„ู…ููˆู…ุฉ
152
00:12:10,700 --> 00:12:15,480
ู‡ูŠูˆุฑุงู† Hodgkin lymphoma ูˆุทุจุนุง
153
00:12:15,480 --> 00:12:18,880
ุฃู†ุง ู…ุด ูƒุชูŠุฑ ู…ุนู†ู‰ ุฃู†ูŠ ุฃุฑูƒุฒู„ูƒูˆุง ุนู„ู‰ ู‡ุฐุง ุงู„ู…ุฑุถ ุงู„ุตุญูŠุญ
154
00:12:18,880 --> 00:12:22,980
ู„ุฃู† ู‡ูˆ disease of pathologist ุฃูƒุชุฑ ู…ู†ู‡ disease of
155
00:12:22,980 --> 00:12:27,220
AIof a hematologist ูˆู‡ุฐู‡ ุชู‚ุณูŠู…ุงุช ุงู„ู€ non-Hodgkin
156
00:12:27,220 --> 00:12:31,240
lymphoma ุฃุฑุจุนุฉ stages ู†ูุณ ุงู„ุญูƒุงูŠุฉ according to the
157
00:12:31,240 --> 00:12:35,940
age while staging ุงูŠูˆุฉ ู‡ุฐุง ุทุจุนุง ุฒูŠ ุงู†ูƒู… ุจุชุนุฑููˆุง
158
00:12:35,940 --> 00:12:39,340
ุงู†ู‡ ู‚ุณู… ุงู„ุงู†ุณุงู† ุงู„ู‰ two sides ุงู„ู„ูŠ ููˆู‚ ุงู„ upper ูˆ
159
00:12:39,340 --> 00:12:43,460
ุงู„ lower ู‡ู‰ involvement of one of lymph node in
160
00:12:43,460 --> 00:12:47,360
one side ุงูƒุชุฑ ู…ู† lymph nodes ู„ูƒู† on the same side
161
00:12:47,360 --> 00:12:52,180
ู‡ู†ุง lymph node involvement in both sides ุซู… ูู‰
162
00:12:52,180 --> 00:12:59,230
extraู…ูˆุถู„ organ involved in bone marrow ููŠ ุงู„ุขุฎุฑ ูˆ
163
00:12:59,230 --> 00:13:06,230
liver are involved classification according to the
164
00:13:06,230 --> 00:13:13,150
infiltration of cells in biopsy ุฌุงู„ู‡ ููŠ ุชู„ุช ุฃู†ูˆุงุน
165
00:13:13,150 --> 00:13:15,750
low grade lymphoma intermediate grade lymphoma and
166
00:13:15,750 --> 00:13:20,210
high grade lymphoma ูˆ treatment ุงู„ lymphoma ุงู„ู„ูŠ
167
00:13:20,210 --> 00:13:23,910
with follicular patternุงู„ู„ูŠ ู‡ู…ุง less aggressive
168
00:13:23,910 --> 00:13:27,050
than those with diffuse batter ูˆุจูŠุญุชุงุฌูˆุง ุฅู„ู‰ less
169
00:13:27,050 --> 00:13:30,650
treatment small lymphocytic lymphoma ุฃูŠุถุง less
170
00:13:30,650 --> 00:13:39,570
aggressive than large ูˆ .. ู‡ุฐู‡ ุดุฑูŠุญุฉ ุงุญู†ุง ุญูƒูŠู†ุงู‡ุง
171
00:13:39,570 --> 00:13:44,470
ู‚ุจู„ ู‡ูŠูƒ ุทุจุนุง ุจุงู„ู…ู‚ุงุฑู†ุฉ ุจุงู„ู€ acute leukemia ุจุนุถ
172
00:13:44,470 --> 00:13:47,190
ุงู„ุญุงู„ุงุช ู…ู† ุงู„ู€ high grade lymphoma ุนุงุฑู‚ุฉ ู…ู†ู‡ุง
173
00:13:47,190 --> 00:13:53,020
ุจูˆู„ูˆุชูˆ treatment ูŠุนู†ูŠ ู‚ุงุจู„ุฉ ู„ู„ุนู„ุงุฌ ุจูŠู†ู…ุงุจุงู„ู…ู‚ุงุฑู†ุฉ
174
00:13:53,020 --> 00:13:55,620
ู…ุน ุงู„ู€ Hodgkin disease ู…ุน ุงู„ู€ Hodgkin lymphoma
175
00:13:55,620 --> 00:14:01,760
usually is disseminated at presentation ูˆุจู‡ูŠูƒ ุจูƒูˆู†
176
00:14:01,760 --> 00:14:11,820
ุงู†ู‡ูŠุช ุงู„ู…ุญุงุถุฑุฉ ูˆุงู†ู‡ูŠุช ุงูŠุถุง ุงู„ู…ู‡ุฏ ุฏู‡ ูˆุดูƒุฑุง
177
00:14:11,820 --> 00:14:19,020
ู„ุงุณุชู…ุงุนูƒู… ู…ุนู†ุง ุงุฑุฌูˆุง ุงู† ุชูƒูˆู†ูˆุง ู‚ุฏ ุงุณุชู…ุชุนุชู… ู…ุนู†ุง